Sugi Predict

Sugi Predict / Compounds / SCHEMBL1499121

SCHEMBL1499121

SCHEMBL1499121

N#CCC(CN1CCN(S(=O)(=O)c2ccccc2C#N)CC1)n1cc(-c2ncnc3[nH]ccc23)cn1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TYRO3 Q06418 3/20 0.59
▸ AXL P30530 2/20 0.55
▸ MERTK Q12866 1/20 0.55
▸ JAK2 O60674 16/20 0.55
▸ JAK1 P23458 15/20 0.55
▸ JAK3 P52333 8/20 0.51
▸ RET P07949 3/20 0.51
▸ ROCK1 Q13464 3/20 0.51
▸ TYK2 P29597 3/20 0.51
▸ DAPK3 O43293 2/20 0.51
▸ PAK4 O96013 2/20 0.51
▸ ABL1 P00519 2/20 0.51
▸ LTK P29376 2/20 0.51
▸ CSNK1A1 P48729 2/20 0.51
▸ CLK2 P49760 2/20 0.51
▸ TNK2 Q07912 2/20 0.51
▸ DYRK1A Q13627 2/20 0.51
▸ IKBKE Q14164 2/20 0.51
▸ NTRK3 Q16288 2/20 0.51
▸ NTRK2 Q16620 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1499335 0.97 TYRO3 (0.56) TYRO3AXLMERTKJAK2JAK1
SCHEMBL2086258 0.93 JAK2 (0.51) TYRO3AXLMERTKJAK2JAK1
SCHEMBL1499221 0.90 JAK2 (0.48) TYRO3JAK2JAK1JAK3RET
SCHEMBL1499058 0.89 TYRO3 (0.57) TYRO3AXLMERTKJAK2JAK1
SCHEMBL2084621 0.89 TYRO3 (0.55) TYRO3AXLMERTKJAK2JAK1
SCHEMBL1499382 0.87 TYRO3 (0.55) TYRO3AXLMERTKJAK2JAK1
SCHEMBL1499410 0.86 JAK2 (0.63) TYRO3AXLMERTKJAK2JAK1
SCHEMBL1499395 0.86 TYRO3 (0.58) TYRO3AXLMERTKJAK2JAK1
SCHEMBL2086141 0.86 TYRO3 (0.52) TYRO3AXLMERTKJAK2JAK1
SCHEMBL1499105 0.85 TYRO3 (0.63) TYRO3AXLMERTKJAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9249145-B2 Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors INCYTE HOLDINGS CORPORATION (US) 2016-02-02 — — US claimed
WO-2011028685-A1 HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-D]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION (US) 2011-03-10 — — WO claimed
US-20110059951-A1 HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION 2011-03-10 — — US claimed
US-9249145-B2 Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors INCYTE HOLDINGS CORPORATION (US) 2016-02-02 — — US disclosed
US-20110059951-A1 HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION 2011-03-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059951-A1 HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS JAK3, JAK1, JAK2 TYRO3 107/4885AXL 296/4885MERTK 515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.